Comment
Author: Admin | 2025-04-28
Explore a selection of our essential drug information below, or:DescriptionA medication used to treat nausea and vomiting during chemotherapy or after operations.DescriptionA medication used to treat nausea and vomiting during chemotherapy or after operations.DrugBank IDDB00904TypeSmall MoleculeUS ApprovedYESOther ApprovedYESTherapeutic CategoriesAntiemetics Serotonin 5-HT3 Receptor Antagonists Mechanism of Action5-hydroxytryptamine receptor 3AAntagonistSummaryOndansetron is a serotonin 5-HT3 receptor antagonist used to prevent nausea and vomiting in cancer chemotherapy and postoperatively.Brand NamesZofran, ZuplenzGeneric NameOndansetronDrugBank Accession NumberDB00904BackgroundA competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.Having been developed in the 1980s by GlaxoSmithKline and approved by the US FDA since January 1991, ondansetron has demonstrated a long history of use and efficacy. Commonly formulated as oral tablets, orally disintegrating tablets (ODT), and injections, and available as generic products as well, ondansetron continues to see contemporary innovations in its formulation and use, including the development of orally soluble films that are both discreet in administration and less of a burden in comparison to having patients attempt to swallow pills during emesis.7The FDA withdrew its approval for the use of all intravenous drug products containing more than 16 mg of ondansetron hydrochloride in a single dose, due to a high risk of QT prolongation.8,9TypeSmall MoleculeGroupsApproved, WithdrawnStructureWeightAverage: 293.363 Monoisotopic: 293.152812245 Chemical FormulaC18H19N3OSynonymsOndansetronIndicationIn the adult patient population:i) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for:- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and- the prevention and treatment of postoperative nausea and vomitingii) intravenously administered ondansetron injection formulations are indicated for:- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and- the prevention and treatment of postoperative nausea and vomitingIn the pediatric (4-18 years of age) patient population:i) ondansetron was effective and well tolerated when given to children 4-12 years of age for the treatment of post-chemotherapy induced nausea and vomiting,ii) ondansetron tablets,
Add Comment